Rosetta Genomics Gets Extension from Nasdaq to Regain Compliance

Rosetta received an extension to come into compliance with one regulation, but it was notified this week that it is now not in compliance with the $1 per share closing price requirement.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.